Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 3 clients • 6 examiners • 5 art units • 0 of 7 (0%) have an AI response strategy ready
ST. ONGE STEWARD JOHNSTON & REENS LLC manages 4257 career applications in the Biotechnology & Pharmaceuticals technology area. The firm has achieved a resolved allowance rate pct of 83.73. Its prosecution history includes an avg office actions per allowance of 2.96.
There are 8 pending office actions currently active. The 83.73 resolved allowance rate pct for its 4257 career applications indicates the firm's success in securing allowances. An avg office actions per allowance of 2.96 provides a benchmark for the examination process in its primary technology area.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (43%) |
| Multi-statute (no §101) | 4 (57%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIPPERT, JOHN WILLIAM | 2 | 58.2% | +40.0% |
| GROUX, JENNIFER LILA | 1 | 34.8% | +39.3% |
| NGUYEN, JOHN P | 1 | 43.9% | +41.8% |
| KAMM, JUDITH MARIE | 1 | 43.5% | +56.6% |
| MCLEOD, AFRICA MHAIRIE | 1 | 51.9% | +67.5% |
| COUGHLIN, DANIEL F | 1 | 39.0% | +18.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17783818 | Dot Printing Method And Device For Additive Manufacturing Of Dosage Forms Which Contain Active Substances | GROUX, JENNIFER LILA | 73d overdue |
| 17639113 | Minimal Messenger RNAs and uses thereof | MCLEOD, AFRICA MHAIRIE | 19d overdue |
| 18001582 | Pharmaceutical Compositions Containing Enterokine Releasing Substances In Multiple Dosage Forms In Combination With Gelling Agents | NGUYEN, JOHN P | 9d |
| 17615431 | Additive Method For 3D Printing Active Ingredient-Containing Objects | KAMM, JUDITH MARIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17783818 | Dot Printing Method And Device For Additive Manufacturing Of Dosage Forms Which Contain Active Substances | GROUX, JENNIFER LILA | 73d overdue |
| 18258742 | Method For Producing Patient-Optimised Dosage Forms | LIPPERT, JOHN WILLIAM | 60d overdue |
| 17639113 | Minimal Messenger RNAs and uses thereof | MCLEOD, AFRICA MHAIRIE | 19d overdue |
| 18001582 | Pharmaceutical Compositions Containing Enterokine Releasing Substances In Multiple Dosage Forms In Combination With Gelling Agents | NGUYEN, JOHN P | 9d |
| 17615559 | Polyvalent Dosage Forms and Method For Their Production | COUGHLIN, DANIEL F | 40d |
| 17615431 | Additive Method For 3D Printing Active Ingredient-Containing Objects | KAMM, JUDITH MARIE | — |
| 17615450 | Pharmaceutical Dosage Forms and Method For Their Production | LIPPERT, JOHN WILLIAM | — |
| Client (Assignee) | Pending OAs |
|---|---|
| DiHeSys Digital Health Systems | 5 |
| APHAIA IP AG | 1 |
| University of Zurich | 1 |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| 1619 | 2 |
| 1754 | 1 |
| 1611 | 1 |
| 1635 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18258742 | Method For Producing Patient-Optimised Dosage Forms | Dihesys Digital Health Systems GmbH | LIPPERT, JOHN WILLIAM | 1615 | §103 | Final Rejection | 60d overdue | Pending | Oct 12, 2023 |
| 17783818 | Dot Printing Method And Device For Additive Manufacturing Of Dosage Forms Which Contain Active Substances | Dihesys Digital Health Systems GmbH | GROUX, JENNIFER LILA | 1754 | §103§112 | Final Rejection | 73d overdue | Pending | Dec 14, 2022 |
| 18001582 | Pharmaceutical Compositions Containing Enterokine Releasing Substances In Multiple Dosage Forms In Combination With Gelling Agents | Aphaia Ip AG | NGUYEN, JOHN P | 1619 | §103§112 | Non-Final OA | 9d | Pending | Dec 12, 2022 |
| 17615431 | Additive Method For 3D Printing Active Ingredient-Containing Objects | Dihesys Digital Health Systems GmbH | KAMM, JUDITH MARIE | 1611 | §103§112 | Non-Final OA | — | Pending | Mar 23, 2022 |
| 17639113 | Minimal Messenger RNAs and uses thereof | UNIVERSITAET ZUERICH | MCLEOD, AFRICA MHAIRIE | 1635 | §102§112 | Final Rejection | 19d overdue | Pending | Feb 28, 2022 |
| 17615450 | Pharmaceutical Dosage Forms and Method For Their Production | Dihesys Digital Health Systems GmbH | LIPPERT, JOHN WILLIAM | 1615 | §103 | Non-Final OA | — | Pending | Nov 30, 2021 |
| 17615559 | Polyvalent Dosage Forms and Method For Their Production | Dihesys Digital Health Systems GmbH | COUGHLIN, DANIEL F | 1619 | §103 | Non-Final OA | 40d | Pending | Nov 30, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial